Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds

Core Points - Idorsia Ltd has announced interim results for its repurchase offer of outstanding convertible bonds totaling CHF 204 million maturing in 2025 and CHF 600 million maturing in 2028, launched on June 25, 2025 [1][2] - The acceptance rates for the repurchase offer were significantly high, with 90.88% of the CB 2025 and 93.63% of the CB 2028 bonds accepted, surpassing the minimum acceptance rate of 85% [2] - An additional acceptance period for the repurchase offer will take place from August 12 to August 18, 2025, with settlement expected around August 26, 2025 [3] Company Overview - Idorsia aims to challenge established medical paradigms by discovering, developing, and commercializing transformative medicines, positioning itself as a leading biopharmaceutical company [5] - The company is headquartered near Basel, Switzerland, and has a strong focus on small-molecule drugs, with a promising in-house development pipeline and partnerships to enhance portfolio value [6]